Sequent Scientific Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Sequent Scientific.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.9%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt

Sep 27

What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You

Sep 05

Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?

Jan 05

What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?

Dec 24

Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?

Dec 12

Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly

Nov 22

Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)

Nov 10

The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It

Oct 20

How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance?

Oct 05

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Sequent Scientific no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:SEQUENT - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	14,494	165	-34	210	N/A
6/30/2024	14,267	55	N/A	N/A	N/A
3/31/2024	13,697	-359	-2	306	N/A
12/31/2023	13,705	-1,285	N/A	N/A	N/A
9/30/2023	14,212	-1,457	286	984	N/A
6/30/2023	14,128	-1,410	N/A	N/A	N/A
3/31/2023	14,209	-1,212	-694	168	N/A
12/31/2022	14,380	-186	N/A	N/A	N/A
9/30/2022	14,207	74	-854	-282	N/A
6/30/2022	14,336	263	N/A	N/A	N/A
3/31/2022	14,128	410	-19	306	N/A
12/31/2021	13,909	529	N/A	N/A	N/A
9/30/2021	13,879	713	-98	417	N/A
6/30/2021	13,869	805	N/A	N/A	N/A
3/31/2021	13,616	954	619	1,148	N/A
12/31/2020	13,153	963	N/A	N/A	N/A
9/30/2020	12,735	793	1,327	1,718	N/A
6/30/2020	12,115	794	N/A	N/A	N/A
3/31/2020	11,792	699	746	1,153	N/A
12/31/2019	11,606	702	N/A	N/A	N/A
9/30/2019	11,147	629	408	726	N/A
6/30/2019	10,822	568	N/A	N/A	N/A
3/31/2019	10,393	487	906	1,160	N/A
12/31/2018	9,902	348	N/A	N/A	N/A
9/30/2018	9,446	160	N/A	N/A	N/A
6/30/2018	8,904	36	N/A	N/A	N/A
3/31/2018	8,478	9	N/A	452	N/A
12/31/2017	10,457	204	N/A	N/A	N/A
9/30/2017	10,302	352	N/A	N/A	N/A
6/30/2017	9,914	184	N/A	N/A	N/A
3/31/2017	6,836	-113	N/A	-72	N/A
12/31/2016	8,797	-349	N/A	N/A	N/A
9/30/2016	7,592	-430	N/A	N/A	N/A
6/30/2016	6,652	-325	N/A	N/A	N/A
3/31/2016	6,062	-200	N/A	-1	N/A
12/31/2015	5,718	-848	N/A	N/A	N/A
9/30/2015	5,297	-848	N/A	N/A	N/A
6/30/2015	4,789	-535	N/A	N/A	N/A
3/31/2015	4,432	-657	N/A	-235	N/A
12/31/2014	3,779	-676	N/A	N/A	N/A
9/30/2014	3,805	-714	N/A	N/A	N/A
6/30/2014	4,467	-1,125	N/A	N/A	N/A
3/31/2014	3,950	-1,103	N/A	-448	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de SEQUENT es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de SEQUENT crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de SEQUENT crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de SEQUENT crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de SEQUENT crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SEQUENT se prevé que sea elevada dentro de 3 años.

Sequent Scientific Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to ₹149

Price target decreased to ₹170

Price target decreased to ₹197

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024)

Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024

Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director

Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million

Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion.

We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt

What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You

Sequent Scientific Limited, Annual General Meeting, Sep 17, 2024

Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API

New minor risk - Share price stability

First quarter 2025 earnings released: EPS: ₹0.26 (vs ₹1.40 loss in 1Q 2024)

Sequent Scientific Limited to Report Q1, 2025 Results on Aug 14, 2024

Full year 2024 earnings released: ₹1.44 loss per share (vs ₹4.88 loss in FY 2023)

Sequent Scientific Limited to Report Q4, 2024 Results on May 15, 2024

Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)

Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024

Third quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.36 loss in 3Q 2023)

Sequent Scientific Limited Announces Executive Changes

Sequent Scientific Limited to Report Q3, 2024 Results on Feb 13, 2024

Sequent Scientific Limited Announces Resignation of Krunal Shah as Company Secretary & Compliance Officer, Effective on February 15, 2024

Sequent Scientific Limited to Report Q2, 2024 Results on Nov 06, 2023

Sequent Scientific Limited Announces Patri Venkat Raghavendra Rao as Chief Financial Officer

Sequent Scientific Limited, Annual General Meeting, Aug 30, 2023

Sequent Scientific Limited to Report Q1, 2024 Results on Aug 10, 2023

Sequent Scientific Limited Announces Discontinuation of Manufacturing Operations At Tarapur, Maharashtra

Full year 2023 earnings released: ₹4.88 loss per share (vs ₹1.67 profit in FY 2022)

Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet

Third quarter 2023 earnings released: ₹0.36 loss per share (vs ₹0.69 profit in 3Q 2022)

Sequent Scientific Limited Announces Resignation of Rahul Mukim as Director

Price target decreased to ₹149

High number of new and inexperienced directors

Second quarter 2023 earnings released: ₹0.15 loss per share (vs ₹0.58 profit in 2Q 2022)

Sequent Scientific Limited (BSE:512529) agreed to acquire Tineta Pharma Private Limited from group of shareholders for INR 2.18 billion.

Sequent Scientific Limited to Report Q2, 2023 Results on Nov 14, 2022

Sequent Scientific Limited, Annual General Meeting, Sep 20, 2022

First quarter 2023 earnings released: ₹0.57 loss per share (vs ₹0.04 profit in 1Q 2022)

Sequent Scientific Limited to Report Q1, 2023 Results on Aug 08, 2022

Investor sentiment improved over the past week

Sequent Scientific Limited Appoints P V Raghavendra Rao as the Chief Financial Officer

Investor sentiment deteriorated over the past week

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Sequent Scientific Limited to Report Q4, 2022 Results on May 25, 2022

Price target decreased to ₹170

High number of new and inexperienced directors

Sequent Scientific Limited Announces Resignation of Tushar Mistry Chief Financial Officer, Effective May 31, 2022

Sequent Scientific Limited Announces Resignation of Mr. Manish Gupta from the Position of CEO

Sequent Scientific Limited Announces Appointment of Rajaram Narayanan as Managing Director

CEO, MD & Executive Director recently sold ₹73m worth of stock

Investor sentiment improved over the past week

CEO, MD & Executive Director recently sold ₹84m worth of stock

CEO, MD & Executive Director recently sold ₹23m worth of stock

CEO, MD & Executive Director recently sold ₹27m worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to ₹197

Insider recently sold ₹5.7m worth of stock

Investor sentiment deteriorated over the past week

Insider recently bought ₹1.4m worth of stock

Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021)

Investor sentiment deteriorated over the past week

Insider recently sold ₹17m worth of stock

Insider recently sold ₹17m worth of stock

Full year 2021 earnings released: EPS ₹3.87 (vs ₹2.87 in FY 2020)

Insider recently sold ₹1.3m worth of stock

Third quarter 2021 earnings released: EPS ₹1.54 (vs ₹0.83 in 3Q 2020)

New 90-day high: ₹232

Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?

Sequent Scientific Limited to Report Q3, 2021 Results on Feb 03, 2021

New 90-day high: ₹215

Investor sentiment improved over the past week

How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?

Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?